



February 12, 2020

The Honorable Laurie Monnes Anderson, Chair  
Senate Health Care Committee  
State Capitol  
900 Court St NE  
Salem, OR 97301

Dear Senator Monnes Anderson:

The Oregon Bioscience Association (OR Bio) and the Biotechnology Innovation Organization (BIO) respectfully oppose SB 1535, which would make a number of changes to existing biopharmaceutical transparency requirements and give a new charge to the Task Force on Fair Pricing of Prescription Drugs.

We are specifically concerned with the authority that SB 1535 gives to the Department of Consumer and Business Services (DCBS) to require a biopharmaceutical manufacturer to report nearly any information DCBS wants related to biopharmaceutical prices. DCBS is authorized to require the information to be submitted in any format and to fine companies up to \$10,000 per day for failure to "promptly" report the requested information. This overly broad authority also brings heightened concern to existing law's failure to protect trade secrets reported to DCBS.

The changes proposed by SB 1535 are substantial enough and consequential enough that they should not be jammed through during a short session. Our members are engaging in good faith compliance with transparency laws. SB 1535 seeks to move the goal posts and make compliance more difficult.

For these reasons, we respectfully urge your no vote on SB 1535. If you have any questions, please do not hesitate to contact us to discuss this further.

Sincerely,

A handwritten signature in blue ink that reads "Liisa Bozinovic".

Liisa Bozinovic  
Executive Director  
Oregon Bioscience Association

A handwritten signature in blue ink that reads "Brian Warren".

Brian Warren  
Director, State Government Affairs  
Biotechnology Innovation Organization

cc: Members, Senate Health Care Committee